Efficacy and tolerability of initial low-dose lenvatinib to treat differentiated thyroid cancer

Some patients with differentiated thyroid cancer (DTC) may require an initial low dose (LD) of lenvatinib. However, few studies have investigated the efficacy of LD lenvatinib. We compared the efficacy and tolerability of lenvatinib at an initial LD to those of the standard initial dose of 24 mg in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Medicine (Baltimore)
Autors principals: Yamazaki, Haruhiko, Iwasaki, Hiroyuki, Takasaki, Hirotaka, Suganuma, Nobuyasu, Sakai, Rika, Masudo, Katsuhiko, Nakayama, Hirotaka, Rino, Yasushi, Masuda, Munetaka
Format: Artigo
Idioma:Inglês
Publicat: Wolters Kluwer Health 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6417556/
https://ncbi.nlm.nih.gov/pubmed/30855484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000014774
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars